These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 14552908)
1. GM1 enhances dopaminergic markers in the brain of aged rats. Goettl VM; Zhang H; Burrows AC; Wemlinger TA; Neff NH; Hadjiconstantinou M Exp Neurol; 2003 Oct; 183(2):665-72. PubMed ID: 14552908 [TBL] [Abstract][Full Text] [Related]
2. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422 [TBL] [Abstract][Full Text] [Related]
3. Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration. Lu W; Wolf ME Brain Res Mol Brain Res; 1997 Oct; 49(1-2):137-48. PubMed ID: 9387873 [TBL] [Abstract][Full Text] [Related]
5. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area. Adelbrecht C; Agid Y; Raisman-Vozari R Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545 [TBL] [Abstract][Full Text] [Related]
6. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Kilbourn MR; Kuszpit K; Sherman P Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034 [TBL] [Abstract][Full Text] [Related]
7. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855 [TBL] [Abstract][Full Text] [Related]
8. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. Teng L; Crooks PA; Dwoskin LP J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873 [TBL] [Abstract][Full Text] [Related]
9. Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat. Barc S; Page G; Barrier L; Garreau L; Guilloteau D; Fauconneau B; Chalon S J Neurochem; 2002 Feb; 80(3):365-74. PubMed ID: 11905985 [TBL] [Abstract][Full Text] [Related]
10. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. Haycock JW; Becker L; Ang L; Furukawa Y; Hornykiewicz O; Kish SJ J Neurochem; 2003 Nov; 87(3):574-85. PubMed ID: 14535941 [TBL] [Abstract][Full Text] [Related]
11. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain. Kilbourn MR; Kemmerer ES; Desmond TJ; Sherman PS; Frey KA Exp Neurol; 2004 Aug; 188(2):387-90. PubMed ID: 15246838 [TBL] [Abstract][Full Text] [Related]
12. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Suzuki M; Desmond TJ; Albin RL; Frey KA Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403 [TBL] [Abstract][Full Text] [Related]
13. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Wilson JM; Levey AI; Bergeron C; Kalasinsky K; Ang L; Peretti F; Adams VI; Smialek J; Anderson WR; Shannak K; Deck J; Niznik HB; Kish SJ Ann Neurol; 1996 Sep; 40(3):428-39. PubMed ID: 8797532 [TBL] [Abstract][Full Text] [Related]
14. In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies. Kilbourn MR; Sherman PS; Kuszpit K Synapse; 2002 Mar; 43(3):188-94. PubMed ID: 11793424 [TBL] [Abstract][Full Text] [Related]
15. Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum. Naudon L; Leroux-Nicollet I; Boulay D; Costentin J J Neural Transm (Vienna); 2001; 108(4):431-44. PubMed ID: 11475010 [TBL] [Abstract][Full Text] [Related]
16. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Frey K; Kilbourn M; Robinson T Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358 [TBL] [Abstract][Full Text] [Related]
17. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350 [TBL] [Abstract][Full Text] [Related]
18. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. Nirenberg MJ; Chan J; Liu Y; Edwards RH; Pickel VM J Neurosci; 1996 Jul; 16(13):4135-45. PubMed ID: 8753875 [TBL] [Abstract][Full Text] [Related]
19. Retinal cholinergic and dopaminergic deficits of aged rats are improved following treatment with GM1 ganglioside. Goettl VM; Wemlinger TA; Fong TG; Neff NH; Hadjiconstantinou M Brain Res; 2000 Sep; 877(1):1-6. PubMed ID: 10980236 [TBL] [Abstract][Full Text] [Related]
20. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Jaber M; Dumartin B; Sagné C; Haycock JW; Roubert C; Giros B; Bloch B; Caron MG Eur J Neurosci; 1999 Oct; 11(10):3499-511. PubMed ID: 10564358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]